A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published in the 1 July 2014 issue of the journal “EMBO” by Prof Sinclair, North BJ, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan extension therapy: IL-6 increases life span via up regulation of its target gene BubR1. Thus, pharmacological formulations encompassing “IL-6 activators” may be used to extend the lifespan of an individual.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How IL-6 increases the expression of BubR1
To cite: Boominathan, Lifespan extension therapy: IL-6 increases life span via up regulation of its target gene BubR1, 3/June/2015, 10.14 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
# Research cooperation